Recombinant monoclonal antibody to Abeta. It is a monoclonal antibody for the treatment of Alzheimer's disease. A phase I clinical trial has been conducted in 2006/07. It is currently being evaluated in a prodromal Alzheimer's Disease population in the Scarlet Road study, a global phase II study of approximately 360 subjects in 100 centers in 15 countries.
Figure 1 Anti-Human Abeta Antibody (TAB-229) in ELISA
ELISA analysis of TAB-229 was performed by coating with recombinant human Beta-amyloid 42 with His & GST Tag (10703-H20E2) (1 μg/mL). Then blocked with BSA and incubated with Anti-Human Abeta Antibody (TAB-229) at a starting concentration of 2.5 ng/mL. The HRP-conjugated goat anti-human IgG as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 2 Anti-Human Abeta Antibody (TAB-229) in WB
Western blot analysis was performed by loading 1 µg (lane 1, Non-Reduced) and 1 µg (lane 2, Reduced) recombinant human Beta-amyloid 42 with His & GST Tag (10703-H20E2) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least 1 hour. Membranes were probed with Anti-Human Abeta Antibody (TAB-229) at a concentration of 1 μg/mL overnight at 4°C on a rocking platform. Then probed with Goat anti-Human IgG HRP secondary antibody at a dilution of 1:8,000 for one hour. Chemiluminescent was detected.
Figure 3 Anti-Human Abeta Antibody in DB
Dot Blot analysis of TAB-229 was performed by coating with Human Abeta Protein (His Tag).
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-228 | Anti-Human Abeta Recombinant Antibody (Solanezumab) | WB, FuncS, IF, Neut, ELISA, FC, IP | IgG1 - kappa |
TAB-227 | Anti-Human Abeta Recombinant Antibody (Ponezumab) | WB, ELISA, IP, FC, FuncS, Neut, IF | IgG2 - kappa |
TAB-253CQ-F(E) | Human Anti-APP Recombinant Antibody; Fab Fragment (TAB-253CQ-F(E)) | ELISA | Humanized Fab |
TAB-0790CLV-S(P) | Mouse Anti-APP Recombinant Antibody; scFv Fragment (TAB-0790CLV-S(P)) | ELISA | Humanized scFv |
TAB-0828CLV-S(P) | Human Anti-APP Recombinant Antibody; scFv Fragment (TAB-0828CLV-S(P)) | ELISA | Mouse scFv |
There are currently no Customer reviews or questions for TAB-229. Click the button above to contact us or submit your feedback about this product.
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TAB-229, RRID: AB_3111888)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.